QT-screen: High-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes

Assay and Drug Development Technologies

Volumn 2, Issue 5, 2004, Pages 507-514

  Meyer, Thomas ^a   Leisgen, Christine ^a   Gonser, Barbara ^b   Günther, Elke ^b  

^a MULTI CHANNEL SYSTEMS MCS GMBH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; QUINIDINE; SOTALOL;

ANIMAL CELL; ARTICLE; AUTOMATION; CELL CULTURE; CLINICAL STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; ELECTROCARDIOGRAPHY; FOWL; GOOD LABORATORY PRACTICE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART VENTRICLE ARRHYTHMIA; HIGH THROUGHPUT SCREENING; HUMAN COMPUTER INTERACTION; IN VITRO STUDY; IN VIVO STUDY; MAMMAL CELL; NONHUMAN; PRACTICE GUIDELINE; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; TOXICITY TESTING;

ACTION POTENTIALS; ANIMALS; CARDIOVASCULAR AGENTS; CELLS, CULTURED; CHICK EMBRYO; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGY; EXTRACELLULAR FLUID; LONG QT SYNDROME; MYOCYTES, CARDIAC; QUINIDINE;

EID: 10244235353     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2004.2.507     Document Type: Article

References (36)

1. Bode G, Olejniczak K, ICH Expert Working Group: ICH topic: the draft ICH S7B step 2: note for guidance on safety pharmacology studies for human pharmaceuticals. Fundam Clin Pharmacol 2002;16:105-118.
2. Barbier A, Caille D: [Regulatory status of safety pharmacology. Implications]. Therapie 2002;57:104-108.
3. Passino C, Magagna A, Conforti F, Buralli S, Kozakova M, Palombo C, Emdin M: Ventricular repolarization is prolonged in nondipper hypertensive patients: role of left ventricular hypertrophy and autonomic dysfunction. J Hypertens 2003;21:445-451.
4. Elming H, Sonne J, Lublin HK: The importance of the QT interval: a review of the literature. Acta Psychiatr Scand 2003;107:96-101.
5. EI-Sherif N, Turitto G: Torsade de pointes. Curr Opin Cardiol 2003;18:6-13.
6. Mikheeva IS, Kheifets LM, Zakharova OV, Astrakhantseva SS: [QT prolongation as risk factor of arrhythmias in patients treated with chronic hemodialysis]. Kardiologiia 2002;42:48-49.
7. Halbach M, Egert U, Hescheler J, Banach K: Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell Physiol Biochem 2003;13:271-284.
8. Egert U, Knott T, Schwarz C, Nawrot M, Brandt A, Rotter S, Diesmann M: MEA-Tools: an open source toolbox for the analysis of multi-electrode data with MATLAB. J Neurosci Methods 2002;117:33-42.
9. Thomas CA Jr, Springer PA, Loeb GE, Berwald-Netter Y, Okun LM: A miniature microelectrode array to monitor the bioelectric activity of cultured cells. Exp Cell Res 1972; 74:61-66.
10. Hämmerle H, Egert U, Mohr A, Nisch W: Extracellular recording in neuronal networks with substrate integrated microelectrode arrays. Biosens Bioelectron 1994;9:691-696.
11. Banach K, Halbach MD, Hu P, Hescheler J, Egert U: Development of electrical activity in cardiac myocyte aggregates derived from mouse embryonic stem cells. Am J Physiol Heart Circ Physiol 2003;284:H2114-H2123.
12. Anyukhovsky EP, Sosunov EA, Feinmark SJ, Rosen MR: Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium: II. In vivo study. Circulation 1997;96:4019-4026.
13. 2+ channels. Cell Physiol Biochem 2004;14:11-22.
14. Ackerman MJ: The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc 1998;73:250-269.
15. Ficker E, Obejero-Paz CA, Zhao S, Brown AM: The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (hERG) mutations. J Biol Chem 2002; 277: 4989-4998.
16. o and C-type inactivation. FEBS Lett 1997;417:43-47.
17. Advani SV, Singh BN: Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol. Drugs 1995;49:664-679.
18. Rizza C, Valderrabano M, Singh BN: Recurrent torsades de pointes after sotalol therapy for symptomatic paroxysmal atrial fibrillation in a patient with end-stage renal disease. J Cardiovasc Pharmacol Ther 1999;4:129-134.
19. Ruffy R: Sotalol. J Cardiovasc Electrophysiol 1993;4:81-98.
20. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N: Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002;25:263-286.
21. Fossa AA, DePasquale MJ, Raunig DL, Avery MJ, Leishman DJ: The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment. J Pharmacol Exp Ther 2002;302: 828-833.
22. Somberg JC: Calcium channel blockers that prolong the QT interval. Am Heart J 1985;109:416-421.
23. Nose I, Kataoka T, Honda Y, Yamada T, Ikeno A, Fukuya F, Minato H, Takeyama K, Hosoki K, Karasawa T: In vitro and in vivo electrocardiographic evaluation of the novel calcium antagonist monatepil on cardiac conduction system. Arzneimittelforschung 1993;43:722-728.
24. Lazzara R: Antiarrhythmic drugs and torsade de pointes. Eur Heart J 1993;14(Suppl H):88-92.
25. Vaughan Williams EM: Delayed ventricular repolarization as an anti-arrhythmic principle. Eur Heart J 1985;6(Suppl D):145-149.
26. Cronk D, et al.: Cell-based high-throughput screening of ion channels using FLIPR and VIPR membrane potential assay technology. Presented at the Society for Biomolecular Screening 7th Annual Conference, 2001, Baltimore, MD.
27. Gonzalez JE, Tsien RY: Improved indicators of cell membrane potential that use fluorescence resonance energy transfer. Chem Biol 1997;4:269-277.
28. Gonzalez JE: Fluorescence technologies for ion transport targets. Presented at Cambridge Healthtech Institute's Eighth Annual High Throughput Technologies, 2001, Philadelphia, PA.
29. Johnston P, et al.: Ionotropic glutamate receptor (iGluR's) HTS assays: comparison of FLIPR and VIPR formats. Presented at Society for Biomolecular Screening 7th Annual Conference, 2001, Baltimore, MD.
30. Loew LM: How to choose a potentiometric membrane probe. In: Spectroscopic Membrane Probes, pp. 139-152. CRC Press, Boca Raton, FL. 1988.
31. Waggoner A: Optical probes of membrane potential. J Membr Biol 1976;27:317-334.
32. 3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur J Pharmacol 2001;430:147-148.
33. Larsen LA, Johnson M, Brown C, Christiansen M, Frank-Hansen R, Vuust J, Andersen PS: Automated mutation screening using dideoxy fingerprinting and capillary array electrophoresis. Hum Mutat 2001;18:451-457.
34. Netzer R, Ebneth A, Bischoff U, Pongs O: Screening lead compounds for QT interval prolongation. Drug Discov Today 2001;6:78-84.
35. Meyer TG, Boven K-H, Guenther E, Fejtl EM: Micro-electrode arrays (MEA): a novel tool in cardiac safety pharmacology to study QT prolongation. Drug Saf 2004;27: 763-772.
36. De Ponti F, Poluzzi E, Vaccheri A, Bergman U, Bjerrum L, Ferguson J, Frenz KJ, McManus P, Schubert I, Selke G, Terzis-Vaslamatzis G, Montanaro N: Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br J Clin Pharmacol 2002;54:171-177.